Research & Development
LTR Pharma launches Roxus nasal spray for ED in the US
15 October 2026 - Australian pharmaceutical company LTR Pharma Limited (ASX: LTP) on Thursday introduced Roxus, a prescription nasal spray for erectile dysfunction (ED), to patients across the United ...
Genezen agrees manufacturing collaboration with Galibra Neuroscience
15 October 2026 - Genezen, a gene therapy contract development and manufacturing organisation (CDMO), announced on Wednesday that it has entered into a manufacturing collaboration with Galibra Neurosc...
FDA grants Breakthrough Therapy Designation to Legacy Healthcare's CINAINU (LH-8)
14 October 2026 - Biopharmaceutical company Legacy Healthcare announced on Tuesday that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to CINAINU (LH-8), its in...
FDA approves Vantis Vascular's 6F CrossFAST model
14 October 2026 - Medical technology company Vantis Vascular announced on Tuesday that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for a new 6 French (6F) model of ...
Blue Lake Biotechnology reports interim data from Phase 1/2a paediatric clinical trial of BLB201
13 October 2026 - Blue Lake Biotechnology Inc, a clinical-stage intranasal vaccine company, on Monday reported the presentation of interim data from the company's Phase 1/2a paediatric clinical t...
ArkBio reports FDA clearance of IND application for AK0406
13 October 2026 - Commercial-stage biopharmaceutical company Shanghai Ark Biopharmaceutical Co Ltd ('ArkBio') announced on Monday that the US Food and Drug Administration (FDA) has granted i...